KRAS Activating Mutation clinical trials at UCSF
2 research studies open to eligible people
A KRAS activating mutation is a genetic change that can lead to cancer. UCSF is conducting trials to find new treatments for lung and pancreatic cancer patients with this mutation. These trials examine the safety and how well the treatments work.
Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
open to eligible people ages 18 years and up
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.
San Francisco, California and other locations
Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
open to eligible people ages 18 years and up
This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
San Francisco, California and other locations
Our lead scientists for KRAS Activating Mutation research studies include Collin Blakely, MD Andrew Ko, MD.
Last updated: